MyPaTH Story Booth 2.0
Interested in sharing your story about health, illness, or research? Patients and caregivers are needed to participate in a research study to help learn more about topics that are important to you and that may improve health and health care. Participation involves one 45-minute session that takes place over the phone. Eligible participants must be able to read and understand English.
MyPaTH Story Booth – COVID-19 Stories
Participants are invited to share how they are maintaining their health during the coronavirus pandemic, or to share what it is like being ill with COVID-19 and/or caring for a loved one who is ill with COVID-19. Participation in this research study involves one 45-minute session that takes place over the phone. Eligible participants must be able to read and understand English.
ARQ-151-312 – Eczema Study
Do you have eczema? You may be able to participate in a study to find out if a new study drug (a cream) works and is safe to use on eczema. This study includes 4 in-person visits, and involves putting on the study cream (or placebo) every night for 28 nights and undergoing one blood draw. Compensation is provided.
DRM-20-012 – Eczema Study
Do you have eczema? You may be able to participate in a study to test whether an investigational study drug called lebrikizumab impacts the effectiveness of certain vaccines (meningococcal vaccines – MCV and tetanus, diphtheria, and pertussis – Tdap) and also if it is safe and if it works in people with eczema. This study involves 7-11 visits over 32 weeks. Compensation is provided.
All of Us Pennsylvania Research Program
You may be able to change the future of medicine. The All of Us PA Research Program is enrolling adults 18 years of age or older. This may be your chance to improve how your children and your children’s children receive medical care.
Janssen Atopic Dermatitis Study
Do you have atopic dermatitis (also called eczema)? You may be able to participate in a study to see if a study drug called bermekimab is safe and useful for treating patients with moderate to severe atopic dermatitis. Participation in this study will last up to 40 weeks and includes up to 36 visits. Compensation is provided.